AKT1 and glioblastoma: TMEM116, for example, is required for lung cancer cell motility and metastasis through PDK1 signaling pathway (Zhang et al., 2021a); TMEM229A suppresses non‐small cell lung cancer progression via inactivating the ERK pathway (Zhang et al., 2021b); inhibition of proliferation by knockdown of TMEM168 in glioblastoma cells via suppression of Wnt/β-Catenin pathway (Xu et al., 2019); TMEM17 promotes malignant progression of breast cancer via AKT/GSK3β signaling (Zhao et al., 2018).